BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells

Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings

By Leave a Comment

Ncardia forms strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services

November 16, 2021, GOSSELIES, Belgium & NEW YORK — Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, announced that it has secured more than $60 million in capital through a strategic partnership with Kiniciti, a U.S.-based investment platform focused on strengthening the cell and gene therapy ecosystem worldwide.  [Read more…]

Cord Blood and Tissue Banking Competitors Consolidate in All Major Markets

By Leave a Comment

Cord blood and tissue banking is the collection and preservation of the valuable cells within the umbilical cord of a newborn for future medical use. For both therapeutic and financial reasons, the cord blood industry has been witnessing record levels of M&A activity in recent years. Today, more than 70% of the global cord blood market is controlled by the world’s 12 largest cord blood banking operators. [Read more…]

Shoreline Biosciences Announces $140M Financing To Advance Pipeline of iPSC-based Cell Immunotherapies

By Leave a Comment

  • Shoreline Biosciences Announces $140M Financing To Advance Its Growing Pipeline Of Next Generation Cell Immunotherapies
  • Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities.

[Read more…]

Stem Cell Stocks: A Complete List from “A” to “Z”

By 3 Comments

Biotech investing has become an increasingly popular in recent years. Whether you’re new to stem cell stocks or you’ve been around the block, now could be a good time to place your bets. The stock market had its largest point drop in recent history on March 9, 2020. On March 12 and March 16, there were two more record-setting point drops. Even though the market has recovered since then, market prices remain attractive across many sectors.

Furthermore, stem cell companies have received substantial support for their use as living therapeutics against COVID-19 induced respiratory complications, such as ARDS. Given these conditions, an intriguing niche within biotech investing is stem cell stocks. [Read more…]

BioInformant's World-Class Clients